BEFORE THE COVID APPEARED THERE IN CHINA...
The “before times” seem like a decade ago, doesn’t it? Those carefree days when hugging friends and shaking hands wasn’t a forbidden thing, when we didn’t have to reach for a mask before leaving our homes, or forage for supplies of hand sanitizer. Oh, for the days when social distancing wasn’t part of our vernacular. Now we are not only prepared we are insisting that everyone adheres to these rules.

In reality, though, it’s only been about seven months since the world learned a new and dangerous corona-virus was in our midst. In the time since Chinese scientists confirmed the rapidly spreading disease in Wuhan was caused by a new corona-virus and posted its genetic sequence on line, an extraordinary amount has been learned about the virus, SARS-CoV-2, the disease it causes, Covid-19, and how they affect us.

Here are some of the things we have learned, and some of the pressing questions we still need answered.
DO WE HAVE ANY GOOD ANSWERS? The worst news is a few of the anticipated Vaccines MIGHT NOT WORK and they are going to shelve them.!!

Please read on.

https://www.statnews.com/2020/08/17/what-we-now-know-about-covid19-and-what-questions-remain-to-be-answered/

FH.

https://www.ctvnews.ca/health/coronavirus/covid-19-vaccine-may-not-work-in-older-people-experts-say-1.4997928

cbsnews media reported that the new coronavirus has infected more than 400,000 Americans and killed nearly 15,000 people in the country. The American surgeon, Dr. Jerome Adams, is at the forefront of the effort, trying to convey a message to the country to continue to maintain a distance from society and proper sanitation to "smooth the curve."

Eli Lilly says its monoclonal antibody cocktail is effective in treating Covid-19

By MATTHEW HERPER @matthewherperOCTOBER 7, 2020Reprints

Eli Lilly said Wednesday a monoclonal antibody treatment is effective in reducing levels of the virus that causes Covid-19 in patients, and also appears to prevent patients from visiting the emergency room or hospital.

Lilly had previously released results for a similar treatment using one antibody, which experts viewed as promising. But the new results, of a combination of two antibodies, appear, based on limited data provided in a press release, to be more robust. The results also appear roughly similar to those Regeneron presented last week of its own cocktail of two monoclonal antibodies. Last Friday, President Trump was treated with the Regeneron monoclonal antibodies.

Monoclonal antibodies are synthetic versions of the antibodies that are one of the main weapons of the immune system. Researchers believed that injecting them into patients could help treat them.

The patients in the study were sick with Covid-19, but had not been admitted to the hospital. Eli Lilly said that in a preliminary analysis the antibody combination reduced the amount of virus in nasal swabs of patients after 11 days.

Key data, including the actual viral loads of patients and the makeup of the study population, were not included in the press release.

In the study, 112 patients received 2.8 grams of each of the antibodies, and 156 received placebo. The difference in viral load was statistically significant at day 11, unlike some doses of Lilly’s single-antibody cocktail. There was also a statistically significant reduction in viral levels three days and seven days after infectionThe treatment also improved symptoms, according to a scored questionnaire, and resulted in fewer hospital and emergency room visits. Visits to the hospital or ER were made by 5.8% of patients in the placebo group, but just 0.9% of those who received the antibody combination. That difference, however, was just barely statistically significant.

Lilly said that it has already begun talking to regulators around the world about its single antibody treatment, and has filed with the Food and Drug Administration for an emergency use authorization. It expects to submit a request for emergency use authorization for the combination therapy next month, after patients are enrolled in clinical trials and supply has been manufactured. It could submit for full FDA approval of the combination treatment by the middle of next year.

Related: Regeneron’s Covid-19 antibody may help non-hospitalized patients recover faster, data shows
Lilly said it anticipates to have as many as 1 million doses of its one-antibody treatment, LY-CoV555, available in the fourth quarter of 2020, with 100,000 available this month. But for the combination therapy, just 50,000 doses will be available in the fourth quarter of 2020.

Both antibody regimens have been well-tolerated, with no serious side effects, the company said. In the single-antibody studies, there have been reactions to the infusion of the treatment, which is given intravenously, including two “serious infusion reactions,” from which ALLTHE patients recovered.


FH.

https://www.statnews.com/2020/10/07/eli-lilly-monoclonal-antibody-cocktail-covid-19/

20 M SHOTS are ready and it will be initially rolled out to ESSENTIAL Services and Serious Patients.
STAY SAFE AT ALL TIMES till you get your SHOT, It does save lives lives. hope yours too.

The drug maker Moderna said it would apply on Monday to the Food and Drug Administration to authorize its corona virus vaccine for emergency use.

The first injections may be given as early as Dec. 21 if the process goes smoothly and approval is granted, Stéphane Bancel, the company’s chief executive, said in an interview.

Moderna’s application is based on data that it also announced on Monday, showing that its vaccine is 94.1 percent effective, and that its study of 30,000 people has met the scientific criteria needed to determine whether the vaccine works. The finding from the complete set of data is in line with an analysis of earlier data released on Nov. 16 that found the vaccine to be 94.5 percent effective.

The new data also showed that the vaccine was 100 percent effective at preventing severe disease from the corona virus. The product was developed in collaboration with government researchers from the Vaccine Research Center at the National Institute of Allergy and Infectious Diseases.

Mr. Bancel said the company was “on track” to produce 20 million doses by the end of December, and 500 million to a billion in 2021. Each person requires two doses, administered a month apart, so 20 million doses will be enough for 10 million people.

Shares of Moderna surged nearly 18 percent, to $149.50, by early afternoon, after the company’s announcement Monday.

Moderna is the second vaccine maker to apply for emergency use authorization; Pfizer submitted its application on Nov. 20. Pfizer has said it can produce up to 50 million doses this year, with about half going to the United States. Its vaccine also requires two doses per person.

Speaking on “CBS This Morning” on Monday, Alex M. Azar II, the secretary of the Department of Health and Human Services, reiterated that distribution would begin quickly after the expected approvals of the Pfizer and Moderna vaccines.

“We could be seeing both of these vaccines out and getting into people’s arms before Christmas,” he said.

Asked about the role of states in the distribution process, Mr. Azar said that doses would be shipped out through normal vaccine distribution systems, and governors would be “like air traffic controllers” determining which hospitals or pharmacies receive shipments. While governors will determine which groups are prioritized, he said he hoped that they would follow the federal recommendations. He added that he would speak to governors on Monday afternoon with Vice President Mike Pence.

The first shots of the two vaccines are likely to go to certain groups, including health care workers; essential workers like police officers; people in other critical industries; and employees and residents in nursing homes. On Tuesday, a panel of advisers to the Centers for Disease Control and Prevention will meet to determine how to allocate initial supplies of vaccine.

Mr. Azar said that C.D.C. experts will base their recommendations on the latest data on virus cases around the country.

But generally, “Be thinking people in nursing homes, the most vulnerable, be thinking health care workers who are on the front lines,” he said.

The White House moved quickly on Monday to take credit for the Moderna vaccine’s development.

“President Trump’s Operation Warp Speed is rapidly advancing on a trajectory of success to save millions of American lives — five times faster than any other vaccine in history,” Michael Bars, a spokesman for President Trump, said in an emailed statement.

The hopeful news arrives at a particularly grim moment in the U.S. health crisis. Virus cases have surged and overwhelmed hospitals in some regions, and health officials have warned that the numbers may grow even worse in the coming weeks because of Thanksgiving travel and gatherings. In November alone, there have been more than four million new cases and 25,500 deaths.

More than 70 vaccines are being developed around the world, including 11 that, like Pfizer’s and Moderna’s vaccines, are in large-scale trials to gauge effectiveness.

Moderna’s application for emergency use authorization will include data from its Phase 3 study of 30,000 people. F.D.A. scientists will examine the information, and the application is likely to undergo a final review on Dec. 17 by a panel of expert advisers to the agency, Mr. Bancel said, adding that he expected the advisers to make a decision within 24 to 72 hours. The F.D.A. usually follows the recommendations of its advisory panels.

Officials at Operation Warp Speed, the government’s program to accelerate vaccine development, have said vaccinations could begin within 24 hours after the F.D.A. grants authorization.

Mr. Bancel said that Moderna had not yet begun shipping vaccines across the country, and would not do so until the emergency authorization is granted.

The government has arranged to buy vaccines from both Moderna and Pfizer and to provide it to the public free of charge. Moderna has received a commitment of $955 million from the U.S. government’s Biomedical Advanced Research and Development Authority for research and development of its vaccine, and the United States has committed up to $1.525 billion to buy 100 million doses.

The federal government will also begin a publicity campaign to encourage vaccinations, with ads on radio this week and on TV soon, he said.

In response to a question about how officials can guard against people using money or connections to jump the proverbial line, Mr. Azar vowed to “call out any inequities or injustices that we see.”

Video: It is in the link below.


Hope you get your FREE Shot soon. IT IS EXCELLENT way of avoiding the infection FOR LIFE. Pl.Read


FH.

There will be a publication of the research work provided with Age, its Effectiveness etc., made available which will give us an idea how research was conducted and the tabulations of the Results were arrived at. Please look for your copy through our Canadian Publications and the News Reports.

PLEASE take good care of your health and avoid getting contaminated with Covid 19 at all COSTS.

https://bmglobalnews.com/2020/11/30/covid-19-live-updates-moderna-to-seek-emergency-f-d-a-approval-for-vaccine/

https://www.wsj.com/articles/moderna-to-ask-health-regulators-to-authorize-its-covid-19-vaccine-11606737602